Analyzing TriSalus Life Sciences (NASDAQ:TLSI) and Sharps Technology (NASDAQ:STSS)

TriSalus Life Sciences (NASDAQ:TLSI) and Sharps Technology (NASDAQ:STSS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Institutional & Insider Ownership

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 17.2% of Sharps Technology shares are owned by institutional investors. 32.8% of TriSalus Life Sciences shares are owned by insiders. Comparatively, 8.7% of Sharps Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

TriSalus Life Sciences has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500.

Profitability

This table compares TriSalus Life Sciences and Sharps Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-206.24%	N/A	-236.83%
Sharps Technology	N/A	-110.40%	-73.60%

Analyst Ratings

This is a summary of recent recommendations and price targets for TriSalus Life Sciences and Sharps Technology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	0	0	7	2	3.22
Sharps Technology	0	0	0	0	0.00

TriSalus Life Sciences currently has a consensus target price of $11.79, suggesting a potential upside of 191.01%. Given TriSalus Life Sciences’ stronger consensus rating and higher possible upside, equities research analysts clearly believe TriSalus Life Sciences is more favorable than Sharps Technology.

Earnings and Valuation

This table compares TriSalus Life Sciences and Sharps Technology”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$18.51 million	6.67	-$59.04 million	($2.49)	-1.63
Sharps Technology	N/A	N/A	-$9.84 million	($8.08)	-0.23

Sharps Technology has lower revenue, but higher earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.

Summary

TriSalus Life Sciences beats Sharps Technology on 8 of the 14 factors compared between the two stocks.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

About Sharps Technology

Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.